Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Caroline Louise Johnston has worked on the following 17 EPO patent applications which have been published in the last five years:

EP10742846

IMMUNOGENIC COMPOSITION COMPRISING S. PNEUMONIAE POLYSACCHARIDES CONJUGATED TO CARRIER PROTEINS

IPC classification:
A61K 39/09, A61K 39/385, A61P 43/00
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP11724567

CAPSULAR GRAM-POSITIVE BACTERIA BIOCONJUGATE VACCINES

IPC classification:
A61K 39/085
Agent:
Jones Day
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13168453

Use of alpha-toxin for treating and preventing staphylococcus infections

IPC classification:
A61K 39/40, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP12759083

BIOCONJUGATE VACCINES MADE IN PROKARYOTIC CELLS

IPC classification:
A61K 39/095
Agent:
Jones Day
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14198052

Immunogenic composition

IPC classification:
A61K 39/095, A61K 39/102, A61K 39/116, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13762784

BIOCONJUGATES COMPRISING MODIFIED ANTIGENS AND USES THEREOF

IPC classification:
A61K 39/108, A61K 39/385, A61K 47/48, A61P 31/04
Agent:
Jones Day
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13774455

METHODS OF HOST CELL MODIFICATION

IPC classification:
C12N 1/00
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13788753

PRODUCTION OF RECOMBINANT VACCINE IN E. COLI BY ENZYMATIC CONJUGATION

IPC classification:
A61K 39/09, C12N 15/70
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13815768

METHODS AND COMPOSITIONS RELATING TO CRM197

IPC classification:
A61K 47/48, C07K 14/34, C12N 15/73
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14711232

METHOD OF TREATMENT

IPC classification:
A61K 39/095
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
J A Kemp
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP14727541

IMMUNOGENIC COMPOSITION FOR USE IN THERAPY

IPC classification:
A61K 39/085, A61K 47/48
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15189397

IMMUNOGENIC COMPOSITION

IPC classification:
A61K 39/00, A61K 39/095, A61K 39/102, A61K 39/116, A61K 39/385, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Applicant:
Pfizer Ireland Pharmaceuticals
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Agent:
Pfizer
Status:
GRANT OF PATENT INTENDED
EP14784209

METHODS OF HOST CELL MODIFICATION

IPC classification:
A61K 39/104, C12N 5/10, C12N 15/70, C12N 15/90
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14784210

MODIFIED HOST CELLS AND USES THEREOF

IPC classification:
A61K 39/104, C07K 14/21, C12N 5/10, C12N 15/70
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16193340

IMMUNOGENIC COMPOSITION

IPC classification:
A61K 39/08, C07K 14/33, C12N 15/62
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16192711

IMMUNOGENIC COMPOSITION

IPC classification:
A61K 31/70, A61K 39/085, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15733404

CLOSTRIDIUM DIFFICILE IMMUNOGENIC COMPOSITION

IPC classification:
A61K 39/08, C07K 14/33
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature